Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome

Autor: Ammar Qaid, Zhinan Yin, Adnan Mesmar, Mohammed Alnaggar, Shuzhen Liang, Jibing Chen, Mao Lin, Lizhi Niu, Kecheng Xu
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Oncology
Male
Physiology
medicine.medical_treatment
Cell
lcsh:Physiology
0302 clinical medicine
Irreversible electroporation
Medicine
lcsh:QD415-436
lcsh:QP1-981
Liver Neoplasms
Alanine Transaminase
Median overall survival
Neoplastic Cells
Circulating
Magnetic Resonance Imaging
Killer Cells
Natural
Survival Rate
medicine.anatomical_structure
Electroporation
Treatment Outcome
Liver
Hepatocellular cancer
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Female
Immunotherapy
alpha-Fetoproteins
medicine.medical_specialty
Carcinoma
Hepatocellular
Natural killer cell
lcsh:Biochemistry
03 medical and health sciences
Immune system
Internal medicine
Humans
Aspartate Aminotransferases
Chemoembolization
Therapeutic
Adverse effect
Neoplasm Staging
business.industry
Adverse effects
fungi
medicine.disease
Allogenic natural killer cell
030104 developmental biology
business
Stage iv
Tomography
X-Ray Computed
Zdroj: Cellular Physiology and Biochemistry, Vol 48, Iss 5, Pp 1882-1893 (2018)
ISSN: 1421-9778
1015-8987
Popis: Background/Aims: We evaluated the clinical effectiveness of irreversible electroporation (IRE) in combination with immunotherapy using allogenic natural killer cells (NK) for stage IV hepatocellular carcinoma (HCC). Methods: The study involved 40 patients with stage IV HCC who were divided equally into two groups: 1) simple IRE; and 2) IRE plus allogenic NK cells (IRE-NK); we mainly assessed the overall survival (OS). Results: The effect of the IRE-NK treatment was synergistic, i.e., not only did it enhance immune function, it also decreased alpha-fetoprotein expression and showed significantly good clinical effectiveness. At the median 7.6-month follow-up (range, 3.8–12.1 months), median OS was higher in the IRE-NK group (10.1 months) than in the IRE group (8.9 months, P = 0.0078). Conclusion: IRE combined with allogeneic NK cell immunotherapy significantly increases the median OS of patients with stage IV HCC.
Databáze: OpenAIRE
Externí odkaz: